Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

C2800000

Cortisone acetate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Cortisone 21-acetate, 17α,21-Dihydroxy-4-pregnene-3,11,20-trione 21-acetate, 21-Acetoxy-4-pregnen-17α-ol-3,11,20-trione, 4-Pregnene-17α,21-diol-3,11,20-trione 21-acetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H30O6
CAS Number:
50-04-4
Molecular Weight:
402.48
Beilstein:
2067543
MDL number:
MFCD00003609
UNSPSC Code:
41116107
PubChem Substance ID:
329774751
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

cortisone

manufacturer/tradename

EDQM

mp

237-240 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])C(=O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(C)=O

InChI

1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1

InChI key

ITRJWOMZKQRYTA-RFZYENFJSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cortisone acetate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361d

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yin-Hu Ma et al.
The Journal of steroid biochemistry and molecular biology, 117(4-5), 146-151 (2009-09-12)
An intensive and systematic investigation had been carried out on the Delta(1)-dehydrogenation of cortisone acetate (CA) to prednisone acetate (PA) by Arthrobacter simplex TCCC 11037 in the presence of native and modified beta-cyclodextrins (beta-CDs). The biotransformation was improved through the
Wiebke Arlt et al.
Clinical endocrinology, 64(4), 384-389 (2006-04-06)
Evaluation of glucocorticoid replacement quality in adrenal insufficiency (AI) relies primarily on clinical judgement and thus largely depends on the physician's expertise. It is a matter of debate whether cortisol day curves are of value in assessing glucocorticoid replacement quality.
K Mai et al.
Clinical endocrinology, 63(4), 442-449 (2005-09-27)
Free fatty acids (FFAs) induce hepatic insulin resistance and enhance hepatic gluconeogenesis. Glucocorticoids (GCs) also stimulate hepatic gluconeogenesis. The aim of this study was to investigate whether the FFA-induced hepatic insulin resistance is mediated by increased activity of hepatic 11beta-hydroxysteroid
Ricardo P P Moreira et al.
Clinics (Sao Paulo, Brazil), 66(8), 1361-1366 (2011-09-15)
21-hydroxylase deficiency is an autosomal recessive disorder that causes glucocorticoid deficiency and increased androgen production. Treatment is based on glucocorticoid replacement; however, interindividual variability in the glucocorticoid dose required to achieve adequate hormonal control has been observed. The present study
L Barbetta et al.
Journal of endocrinological investigation, 28(7), 632-637 (2005-10-13)
Since the optimal glucocorticoid replacement needs to avoid over and under treatment, the adequacy of different daily cortisone acetate (CA) doses was assessed in 34 patients with primary and central hypoadrenalism. The conventional twice CA 37.5 mg/day dose was administered
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service